Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

New creative directors at Klick, FCB Health

Soon after his departure from FCB Health during April 2019, Rich Levy had a new job; as chief creative officer of Klick Health. In the wake of Levy’s departure, Dana Maiman – president and CEO of FCB Health Network – announced that Kathleen Nanda was promoted to executive creative director of FCB Health New York.

Read More »

HCB Health appoints Nancy Beesley as president

HCB Health, a leading independent U.S. healthcare advertising agency, appointed HCB Partner Nancy Beesley as president.

Read More »

Evoke acquires specialty health communications agency KYNE

Evoke, part of Huntsworth plc, acquired specialty health communications agency KYNE during May 2019.

Read More »

Drug prices in advertising: Threading a needle of transparency and confusion

Thanks to a finalized rule requiring price disclosure in DTC advertisements (this is assuming that successful legal challenges do not emerge), what will the impact be and how can the requirement be accommodated while minimizing any confusion that may result?

Read More »

Honoring patients while launching a rare disease brand

According to the National Organization for Rare Diseases 2019 Fact Sheet, more than 90 percent of the 7,000 known rare diseases do not have an FDA-approved treatment. It’s a privilege to bring brands to market for the patients, caregivers, families and physicians who so badly need them. In order to effectively launch into the rare disease space, there are elements to consider that take us well beyond standard launch prep. It’s these elements that will set one brand apart from another and contribute to a successful launch.

Read More »

In rare diseases, a strategic product launch can change lives

The statistics are staggering and well-known. Despite an increasing pipeline of drugs targeting rare diseases, 95 percent of the 7,000 disorders classified as rare still have no indicated treatment option. Eighty percent of rare diseases are genetically based, and more than half of the 30 million Americans affected by rare disorders are children. Rare diseases can take five to seven years to be accurately diagnosed, partly because they are inherently difficult to identify and because there are relatively few physicians equipped to recognize and design an appropriate treatment plan for a disorder that will, at most, affect 200,000 people (but often far fewer).

Read More »

String of promotions, appointments at CMI/Compas

In celebrating the company’s 30th year, CMI/Compas expanded the leadership to accommodate explosive growth.

Read More »

Innovation Week at FCB Health focuses on tech advances in healthcare advertising

FCB Health Network held its annual Innovation Week from May 7-9, 2019. Here’s a topline summary for anyone who missed the event.

Read More »

Eisai Inc. makes key executive appointments in Alzheimer’s disease

Eisai Inc., the U.S. pharma subsidiary of Eisai Co. Ltd., continued the expansion of the company’s Alzheimer’s disease business with the appointments of two renowned experts in the neuroscience field. Dr. Harald Hampel joins the company as VP, Global Medical Affairs. Dr. Michael Irizarry has been named VP, Clinical Research. Both executives will work on advancing the company’s extensive pipeline of Alzheimer’s disease and dementia compounds.

Read More »

New president and CEO for AEON Biopharma

ALPHAEON Corp. named Marc Forth as president and CEO of the company’s newly established, wholly owned subsidiary: AEON Biopharma Inc.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom